Fortress Biotech, Inc. (FBIO)
| Market Cap | 311.27M |
| Revenue (ttm) | 52.65M |
| Net Income (ttm) | -33.20M |
| Shares Out | 80.96M |
| EPS (ttm) | -0.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 387,236 |
| Open | 3.12 |
| Previous Close | 3.08 |
| Day's Range | 3.05 - 3.13 |
| 52-Week Range | 2.12 - 6.10 |
| Beta | 2.40 |
| Analysts | Strong Buy |
| Price Target | 10.17 (+230.2%) |
| Est. Earnings Date | Nov 8, 2021 |
About FBIO
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intra...
Financial Performance
In 2020, FBIO's revenue was $45.60 million, an increase of 24.49% compared to the previous year's $36.63 million. Losses were -$46.53 million, 16.4% more than in 2019.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for FBIO stock is "Strong Buy." The 12-month stock price forecast is 10.17, which is an increase of 230.19% from the latest price.
News
Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented...
NEW YORK and SOLANA BEACH, Calif., Oct. 13, 2021 /PRNewswire/ -- Cyprium Therapeutics, Inc. ("Cyprium"), a Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") partner company, with support from its licen...
Fortress' (FBIO) Partner Meets Study Goal for Menkes Disease
Cyprium Therapeutics, a partner company of Fortress Biotech (FBIO), reports positive data from two pivotal studies evaluating CUTX-101 in patients with Menkes disease.
Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented...
Cyprium Therapeutics, a partner company of Fortress Biotech, is developing CUTX-101 for the treatment of Menkes disease
Fortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AstraZeneca
Triggers upfront payment of approximately $150 million to Caelum shareholders, of which approximately $64 million is payable to Fortress Biotech 1
Journey Medical Corporation Appoints Ernest De Paolantonio as Chief Financial Officer
NEW YORK and SCOTTSDALE, Ariz., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”) focused on iden...
Fortress Biotech Announces Receipt of Notice of Option Exercise from AstraZeneca to Fully Acquire Caelum Biosciences,...
Option exercise triggers upfront payment of approximately $150 million to Caelum shareholders, of which approximately $64 million is payable to Fortress Biotech 1
Fortress Biotech to Participate in Three September 2021 Investor Conferences
NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizin...
Fortress Biotech (FBIO) Reports Q2 Loss, Tops Revenue Estimates
Fortress Biotech (FBIO) delivered earnings and revenue surprises of 71.43% and 29.11%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Fortress Biotech Reports Record Second Quarter 2021 Financial Results and Recent Corporate Highlights
Net revenue for second quarter of 2021 increased 89% year-over-year to $17.8 million, a quarterly record
Fortress Biotech (FBIO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Fortress Biotech Stock Is Sinking Today
The FDA refused to approve IV tramadol for the second time.
Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts
Penny stocks to watch with upcoming event dates to keep in mind this week The post Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts appeared first on Penny Stocks to Buy, Picks, N...
Biotech Penny Stocks To Watch For June 2021
These penny stocks are expecting to release key information this month. The post Biotech Penny Stocks To Watch For June 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto...
Diversifying to Conquer: Fortress Biotech (FBIO) Partnering Expansion Driving Progress in Cancer Immunotherapy and Ra...
The following article is sponsored by the clinical communications unit of Redington, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzi...
Fortress Biotech to Participate in Three June 2021 Virtual Investor Conferences
NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing...
REPEAT -- Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate Highlights
Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to begin in the second half of 2021
Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate Highlights
Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to begin in the second half of 2021
4 Biotech Stocks Set to Outpace Q1 Earnings Estimates
Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.
Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad in North America and Eu...
Agreement signed with Fuji Yakuhin to develop Dotinurad, a potential best-in-class urate transporter (URAT1) inhibitor for gout and potentially other hyperuricemic indications including chronic kidney d...
Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
3 Penny Stocks That Wall Street Wants You To Buy Now
Penny stocks are very risky, which is why they have such low prices. Many of the companies in this risky part of the market will go bankrupt.
Why Fortress Biotech Stock Is Sinking Today
Investors were not thrilled with the company's latest regulatory update.
Is the Options Market Predicting a Spike in Fortress Biotech (FBIO) Stock?
Investors need to pay close attention to Fortress Biotech (FBIO) stock based on the movements in the options market lately.
Fortress Biotech (FBIO) Surges 11.5%: Is This an Indication of Further Gains?
Fortress Biotech (FBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price incre...